Hims & Hers Health (NYSE:HIMS) Downgraded by Citigroup to “Sell”

Hims & Hers Health (NYSE:HIMS) was downgraded by research analysts at Citigroup from a “neutral” rating to a “sell” rating in a research note issued on Friday, MarketBeat Ratings reports. They currently have a $25.00 price objective on the stock, up from their prior price objective of $24.00. Citigroup’s price target indicates a potential downside of 1.61% from the stock’s current price.

Several other equities analysts have also weighed in on HIMS. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Needham & Company LLC boosted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Stock Down 1.2 %

Hims & Hers Health stock opened at $25.41 on Friday. The firm has a 50-day moving average price of $27.21 and a two-hundred day moving average price of $21.64. The firm has a market capitalization of $5.55 billion, a price-to-earnings ratio of 57.75 and a beta of 1.31. Hims & Hers Health has a 52-week low of $8.14 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) EPS. Research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,333,446 shares of company stock valued at $34,175,197. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. GAMMA Investing LLC lifted its position in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Quarry LP raised its holdings in Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after acquiring an additional 2,913 shares during the period. Finally, Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.